Streetbeat News

Regulatory

ASLN

Trading halt status for ASLAN Pharmaceuticals (ASLN) was updated at 8:55:00 AM ET. The halt is due to pending news and the resumption times will be announced.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 12:55 pm

ICU

SeaStar Medical shares are trading higher after the company finalized FDA labeling requirements for QUELIMMUNE.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 12:49 pm

DELL

IVW

NVDA

SMCI

VGT

Nvidia Corp (NASDAQ:NVDA) is under scrutiny as its advanced AI chips are reportedly being smuggled into China despite U.S. export restrictions. The underground market for these chips is thriving, with over 70 distributors advertising Nvidia’s restricted chips online. Nvidia sells its chips through third parties like Dell Technologies Inc (NYSE:DELL) and Super Micro Computer Inc (NASDAQ:SMCI). The U.S. government plans to extend its semiconductor technology embargo to Russia. Nvidia stock has gained over 189% in the last 12 months.

Portfolio Pulse from Anusuya Lahiri

July 03, 2024 | 12:31 pm

ICU

SeaStar Medical has finalized the FDA labeling requirement for its QUELIMMUNE product, which is used in intensive care units (ICUs). This development is a significant step towards the product's market launch.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 12:30 pm

MBOT

Microbot Medical has partnered with Baptist Hospital of Miami to participate in a human clinical trial. This collaboration aims to advance the development and testing of Microbot Medical's innovative medical technologies.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 12:23 pm

JNJ

Health Canada has authorized Johnson & Johnson's RYBREVANT in combination with carboplatin and pemetrexed as the first-line treatment for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed significant improvement in progression-free survival.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 12:04 pm

MDAI

Spectral AI has expanded its clinical trial sites for a U.S. burn study to a total of 14 sites. This expansion is expected to accelerate the study and potentially bring their burn treatment technology to market faster.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 12:03 pm

BABAF

PDD

The European Union is considering abolishing the 150 Euro duty-free threshold for online purchases, targeting Chinese retailers like Shein and Temu. This follows similar regulatory challenges faced by these companies in the U.S. The new rules could increase the workload for EU customs officials and require large platforms to register for VAT payments.

Portfolio Pulse from Benzinga Neuro

July 03, 2024 | 11:51 am

ANVS

Annovis Bio, Inc. (NYSE:ANVS) shares are gaining in premarket trading following a 76% increase in the previous session. The company announced positive data from its Phase III Parkinson’s study, showing improvements in the Unified Parkinson’s Disease Rating Scale with its treatment, buntanetap. Additionally, Annovis filed a provisional patent for the manufacturing process of new solid forms of buntanetap.

Portfolio Pulse from Nabaparna Bhattacharya

July 03, 2024 | 11:12 am

SPY

NY Fed President Williams highlighted the uncertainty surrounding the natural rate of interest (R-Star) and its implications for real-time policy decisions. He emphasized the importance of understanding the current level of R-Star.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 11:04 am